These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 39004413)

  • 1. Ketamine metabolism via hepatic CYP450 isoforms contributes to its sustained antidepressant actions.
    Loan Nguyen TM; Guilloux JP; Defaix C; Mendez-David I; Etting I; Alvarez JC; McGowan JC; Highland JN; Zanos P; Lovett J; Moaddel R; Corruble E; David DJ; Gould TD; Denny CA; Gardier AM
    Neuropharmacology; 2024 Nov; 258():110065. PubMed ID: 39004413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (2R,6R)-Hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice.
    Yamaguchi JI; Toki H; Qu Y; Yang C; Koike H; Hashimoto K; Mizuno-Yasuhira A; Chaki S
    Neuropsychopharmacology; 2018 Aug; 43(9):1900-1907. PubMed ID: 29802366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cortical and raphe GABA
    Pham TH; Defaix C; Nguyen TML; Mendez-David I; Tritschler L; David DJ; Gardier AM
    Pharmacol Biochem Behav; 2020 May; 192():172913. PubMed ID: 32201299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (
    Zanos P; Highland JN; Stewart BW; Georgiou P; Jenne CE; Lovett J; Morris PJ; Thomas CJ; Moaddel R; Zarate CA; Gould TD
    Proc Natl Acad Sci U S A; 2019 Mar; 116(13):6441-6450. PubMed ID: 30867285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ketamine treatment involves medial prefrontal cortex serotonin to induce a rapid antidepressant-like activity in BALB/cJ mice.
    Pham TH; Mendez-David I; Defaix C; Guiard BP; Tritschler L; David DJ; Gardier AM
    Neuropharmacology; 2017 Jan; 112(Pt A):198-209. PubMed ID: 27211253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic doses.
    Zanos P; Highland JN; Liu X; Troppoli TA; Georgiou P; Lovett J; Morris PJ; Stewart BW; Thomas CJ; Thompson SM; Moaddel R; Gould TD
    Br J Pharmacol; 2019 Jul; 176(14):2573-2592. PubMed ID: 30941749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (2
    Fukumoto K; Fogaça MV; Liu RJ; Duman C; Kato T; Li XY; Duman RS
    Proc Natl Acad Sci U S A; 2019 Jan; 116(1):297-302. PubMed ID: 30559184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of metabolism in (R)-ketamine's antidepressant actions in a chronic social defeat stress model.
    Zhang K; Fujita Y; Hashimoto K
    Sci Rep; 2018 Mar; 8(1):4007. PubMed ID: 29507385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxynorketamine Pharmacokinetics and Antidepressant Behavioral Effects of (2
    Highland JN; Morris PJ; Konrath KM; Riggs LM; Hagen NR; Zanos P; Powels CF; Moaddel R; Thomas CJ; Wang AQ; Gould TD
    ACS Chem Neurosci; 2022 Feb; 13(4):510-523. PubMed ID: 35113535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (S)-norketamine and (2S,6S)-hydroxynorketamine exert potent antidepressant-like effects in a chronic corticosterone-induced mouse model of depression.
    Yokoyama R; Higuchi M; Tanabe W; Tsukada S; Naito M; Yamaguchi T; Chen L; Kasai A; Seiriki K; Nakazawa T; Nakagawa S; Hashimoto K; Hashimoto H; Ago Y
    Pharmacol Biochem Behav; 2020 Apr; 191():172876. PubMed ID: 32088360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP 450 enzymes influence (R,S)-ketamine brain delivery and its antidepressant activity.
    Nguyen TML; McGowan JC; Gardier AM
    Neuropharmacology; 2022 Mar; 206():108936. PubMed ID: 34965407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal (R, S)-ketamine delivery induces sustained antidepressant effects associated with changes in cortical balance of excitatory/inhibitory synaptic activity.
    Nguyen TML; Defaix C; Mendez-David I; Tritschler L; Etting I; Alvarez JC; Choucha W; Colle R; Corruble E; David DJ; Gardier AM
    Neuropharmacology; 2023 Mar; 225():109357. PubMed ID: 36462636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sex-dependent metabolism of ketamine and (
    Highland JN; Farmer CA; Zanos P; Lovett J; Zarate CA; Moaddel R; Gould TD
    J Psychopharmacol; 2022 Feb; 36(2):170-182. PubMed ID: 34971525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of Antidepressant Effects of (2R,6R)-Hydroxynorketamine in a Rat Learned Helplessness Model: Comparison with (R)-Ketamine.
    Shirayama Y; Hashimoto K
    Int J Neuropsychopharmacol; 2018 Jan; 21(1):84-88. PubMed ID: 29155993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (
    Highland JN; Morris PJ; Zanos P; Lovett J; Ghosh S; Wang AQ; Zarate CA; Thomas CJ; Moaddel R; Gould TD
    J Psychopharmacol; 2019 Jan; 33(1):12-24. PubMed ID: 30488740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (2R,6R)-hydroxynorketamine rescues chronic stress-induced depression-like behavior through its actions in the midbrain periaqueductal gray.
    Chou D; Peng HY; Lin TB; Lai CY; Hsieh MC; Wen YC; Lee AS; Wang HH; Yang PS; Chen GD; Ho YC
    Neuropharmacology; 2018 Sep; 139():1-12. PubMed ID: 29953886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ketamine increases vmPFC activity: Effects of (R)- and (S)-stereoisomers and (2R,6R)-hydroxynorketamine metabolite.
    Hare BD; Pothula S; DiLeone RJ; Duman RS
    Neuropharmacology; 2020 Apr; 166():107947. PubMed ID: 31926944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of the sustained antidepressant-like effect of (2R,6R)-hydroxynorketamine in NMDA receptor GluN2D subunit knockout mice.
    Yamagishi A; Ikekubo Y; Mishina M; Ikeda K; Ide S
    J Pharmacol Sci; 2024 Mar; 154(3):203-208. PubMed ID: 38395521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antidepressant-relevant concentrations of the ketamine metabolite (2
    Lumsden EW; Troppoli TA; Myers SJ; Zanos P; Aracava Y; Kehr J; Lovett J; Kim S; Wang FH; Schmidt S; Jenne CE; Yuan P; Morris PJ; Thomas CJ; Zarate CA; Moaddel R; Traynelis SF; Pereira EFR; Thompson SM; Albuquerque EX; Gould TD
    Proc Natl Acad Sci U S A; 2019 Mar; 116(11):5160-5169. PubMed ID: 30796190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological evaluation of clinically relevant concentrations of (2R,6R)-hydroxynorketamine.
    Shaffer CL; Dutra JK; Tseng WC; Weber ML; Bogart LJ; Hales K; Pang J; Volfson D; Am Ende CW; Green ME; Buhl DL
    Neuropharmacology; 2019 Jul; 153():73-81. PubMed ID: 31015046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.